UK Health Committee issues 3-year report on NICE (UK National Institute for Clinical Excellence):
This article was originally published in Clinica
Executive Summary
As Clinica went to press, the UK House of Commons Select Committee for Health published its report of the first three years of operation of the National Institute for Clinical Excellence (NICE). The institute's chairman, Professor Sir Michael Rawlins, welcomed the assessment as a thorough, important and positive exercise. "There is much to consider", he said, regarding proposals to reform NICE's approach to what is a "challenging remit". NICE is to discuss the report at its annual general meeting, on July 17; a more detailed response will be agreed at the institute's board meeting, in September.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.